Tom Vanden Berghe

📰 New paper alert! In case you missed it over the holidays: my News & Views on the latest work from the Linkermann Lab is out. rdcu.be/eBIqZ Congrats to the Linkermann team on this exciting study! 🎉 #ScienceTwitter #CellDeath #Research @Nature nature.com/articles/d4158…

@eikan_em @Linkermann_Lab Strong story with impact. Top!

@Linkermann_Lab Congrats!

Glad to share our open access nature paper. Congrats to the three first authors and thanks to everyone involved! nature.com/articles/s4158…

Game changer in translational ferroptosis research. Check out this nature paper by Linkermann lab and his amazing team ! Oestrogen defends against kidney damage caused by iron-dependent cell death nature.com/articles/d4158…

Mads Daugaard is striking again. High level of translational oncology presented @EWCD meeting in Fiuggi Italy.

Registration for ECDO2025 is now officially open. Secure your place at the legendary event in Berlin today ecdo.eu/ecdo2025/conte…

⚡️SAVE the DATE!!!! SAVE the DATE!!!!⚡️

Harnessing ferroptosis for precision oncology: challenges and prospects. New #openaccess Review from Fernández-Acosta @TomVBerghe and co as part of our ‘#Ferroptosis’ Collection bmcbiol.biomedcentral.com/articles/10.11…

This is such an accurate representation of being a PhD student

🚀 Exciting opportunity! 🎓 The PhD program in Cancer and Immunology in Lausanne is accepting applications! If you're passionate about advancing research in cancer or immunology, we want to hear from you! 🌟 #PhD #CancerResearch #Immunology unil.ch/cancer-immunol… via @unil

@bruno_de_geest Interesting. Can you send me pdf?

Lysosomal Trafficking and Degradation of Extracellular Proteins via Multivalent Small Molecule Ligand Display on Dextran Scaffolds | Biomacromolecules pubs.acs.org/doi/10.1021/ac…

Knappe koppen vrt.be/vrtmax/a-z/kna… Don't forget to watch tonight! Niet vergeten kijken deze avond.

The human proteomic revolution proceeds with high-throughput assessment, AI analytics, correlation with health and disease, drug interactions, biomarkers cell.com/cell/fulltext/…

While at @DanaFarber, Brian Bruker (now @OHSUKnight) started the personalized medicine revolution with the first targeted cancer drug, imatinib. The first of a series of BCR-ABL inhibitors that made Ph+ #CML a chronic disease. A transformative discovery.

Interested in our work? Watch 'Knappe koppen' on national TV VRT1 Wednesday Dec 4 at 21h35. Geinteresseerd in ons werk? Kijk 'knappe koppen' op VRT1 woensdag 4 dec 21h35 vrt.be/nl/over-ons/ni…

Another memorable CSHA ferroptosis meeting in Suzhou China. Thx to organisers and cell death community! @CSHANews #ferroptosis

Big congrats to Geraldine Veeckmans for poster price award ⁦@CSHANews⁩. Let’s translate ferroptosis inhibitors to clinic! ⁦@FWOVlaanderen⁩ #ferroptosis

Very cool - congratulations! First ferroptosis conference in the 🇺🇸 Looking forward to it!

@Conrad_Lab @bstockwell Really pity I had to miss this memorable moment. Major achievement to be proud of. Congrats to both of you

What an honour to be receiving this year’s ECDO awards 🏆🏆 along with @bstockwell ! For a biologist 🐁, there is nothing more to wish for than to continue trailblazing this field with my comrade and excellent chemist 🧪 Brent!

@ECDOorg @bstockwell @cddpress Congrats Brent. Major achievement. Pity I missed it due to emergency surgery to my back. @bstockwell

Congratulations to Brent Stockwell @bstockwell for the 2024 CDD prize @cddpress for his key contributions in the cell death field with the discovery of #ferroptosis

Cell Death-Related Ubiquitin Modifications in Inflammatory Syndromes: From Mice to Men mdpi.com/1682504 #mdpibiomedicines via @Biomed_MDPI